logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics CEO talks recent RNAi deals and updates on critical SLN124 trial

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran.

Solomon also updates on their lead candidate, SLN124, which is being developed to treat iron overload disorders.

Quick facts: Silence Therapeutics PLC

Price: 421 GBX

AIM:SLN
Market: AIM
Market Cap: £348.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics - Proactive One2One Virtual Event

Rob Quinn, from Silence Therapeutics (LON:SLN) pitches the company to investors at the Proactive One2One Virtual Event. Silence develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can...

5 days, 1 hour ago

2 min read